ArticleJournal of gastrointestinal oncology2018

Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy.

Samuel J Klempner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.